| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,562,435 | 9 | 100 |
| Levy Raphi | Chief Financial Officer | 0 | $0 | 9 | $1.56M | $-1.56M |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Over the last 12 months, insiders at Alpha Tau Medical Ltd have bought $0 and sold $1.56M worth of Alpha Tau Medical Ltd stock.
On average, over the past 5 years, insiders at Alpha Tau Medical Ltd have bought $0 and sold $1.56M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-08-21 | Sale | Levy Raphi | Chief Financial Officer | 2,871 0.0032% | $15.00 | $43,073 | -3.28% | |
| 2026-08-11 | Sale | Levy Raphi | Chief Financial Officer | 17,730 0.0193% | $14.00 | $248,277 | +0.98% | |
| 2026-07-06 | Sale | Levy Raphi | Chief Financial Officer | 2,270 0.0026% | $14.00 | $31,783 | +2.80% | |
| 2026-07-02 | Sale | Levy Raphi | Chief Financial Officer | 17,873 0.0194% | $13.00 | $232,397 | +5.18% | |
| 2026-07-01 | Sale | Levy Raphi | Chief Financial Officer | 2,127 0.0024% | $13.02 | $27,691 | +9.73% | |
| 2026-06-30 | Sale | Levy Raphi | Chief Financial Officer | 20,000 0.0211% | $12.00 | $240,044 | +9.74% | |
| 2026-06-25 | Sale | Levy Raphi | Chief Financial Officer | 20,000 0.0218% | $11.00 | $220,004 | +21.75% | |
| 2026-06-23 | Sale | Levy Raphi | Chief Financial Officer | 17,500 0.0189% | $9.55 | $167,051 | +38.57% | |
| 2026-06-03 | Sale | Levy Raphi | Chief Financial Officer | 32,500 0.0368% | $10.83 | $352,115 | +26.75% |
| Increased Positions | 14 | +35.9% | 713,070 | +38.91% |
| Decreased Positions | 13 | -33.33% | 278,143 | -15.18% |
| New Positions | 9 | New | 600,087 | New |
| Sold Out Positions | 6 | Sold Out | 160,914 | Sold Out |
| Total Postitions | 40 | +2.56% | 2M | +23.73% |